In the fast-paced and ever-evolving world of biopharma, South Korea continues to assert itself as a global leader, driving innovation through sustained R&D investment and groundbreaking initiatives from both the public and private sectors. South Korea’s exceptional performance in public health during the Covid-19 pandemic has solidified its reputation as a biotech powerhouse on the international stage.
As we look to the future, the 14th Biologics Manufacturing Korea 2025 aims to serve as the premier platform for collaboration, knowledge exchange, and strategic partnerships. This year's conference will delve into critical topics, including advanced strategies in upstream processing, the future of biomanufacturing through automation and AI technologies, insights on regulatory pathways for biosimilars and innovative approaches to downstream processing and supply chain optimization.
Biologics Manufacturing Korea 2025 will be co-located with the CGT East Asia 2025 and ADC & Bioconjugate East Asia 2025 events, enhancing the opportunity for interdisciplinary discussions and collaboration.
Join us at Biologics Manufacturing Korea 2025 to connect with key players shaping Korea’s biopharma landscape, including leaders from Samsung Biologics, Celltrion, SK bioscience, Hanmi Pharmaceuticals, Lotte Biologics, and more. If Korea is your gateway to growth in the biomanufacturing space, Biologics Manufacturing Korea 2025 is the destination where innovation meets opportunity.
